Cannabidiol Oral Solution for Treatment of Refractory Infantile Spasms

Spasms, Infantile Clinical Trial

Official title:

A Phase 2 Study to Assess the Efficacy and Safety of Cannabidiol Oral Solution for the Treatment of Refractory Infantile Spasms

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02551731
• Other study ID #: INS011-15-054
• Status: Terminated
• Phase: Phase 2
• Start date: January 27, 2016
• Est. completion date: September 6, 2016

Study information

• Verified date: August 2018
• Source: INSYS Therapeutics Inc
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Infantile Spasms (IS) is a diagnosis described as a fairly rare and terrible form of epilepsy that usually strikes children in the first year of life. There is a great need for safe and effective therapies in the treatment of IS. This need is even more important for infants and toddlers still sick after being treated with medicine that is already available.

This is a multi-center study to evaluate the efficacy and safety of Cannabidiol Oral Solution (CBD) in the treatment of children aged 6 months through 36 months with a diagnosis of infantile spasms who have not responded to first line therapies.

The overall study duration is expected to be 64 weeks for those subjects who respond to CBD treatment. The maximum possible study duration for each patient is approximately 64 weeks, however a subject will be deemed to have completed the study after 58 weeks.

Description:

A protocol amendment in May 2016 created two parts to this trial: Part A (the extended treatment period) and Part B (the safety treatment period), whose objectives are as follows:

Primary Part A: To evaluate the efficacy of Cannabidiol Oral Solution in treating refractory infantile spasms (IS).

Secondary:

Part A:

• To evaluate the safety of Cannabidiol Oral Solution in treating refractory infantile spasms.

Part B:

• To assess the long-term safety of Cannabidiol Oral Solution as an adjunctive treatment for subjects with Infantile Spasms (IS)

• To establish the continued efficacy of Cannabidiol Oral Solution in maintaining seizure control in subjects with IS

• To assess the global status of subjects taking Cannabidiol Oral Solution for an extended period of time determined by various qualitative assessments

• To monitor for changes in plasma levels of Cannabidiol Oral Solution during long-term treatment of subjects with IS

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 9
• Est. completion date: September 6, 2016
• Est. primary completion date: September 6, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 6 Months to 36 Months

Eligibility

Inclusion Criteria:

• Meets protocol-specified criteria for qualification, including infantile spasms

• Parent(s)/caregiver(s) fully comprehend and sign the informed consent form, understand all study procedures, and can communicate satisfactorily with the Investigator and study coordinator.

Exclusion Criteria:

• History or current use of over-the-counter medications, dietary supplements, or drugs outside protocol-specified parameters

• Signs, symptoms or history of any condition that, per protocol or in the opinion of the investigator, might compromise:

1. the safety or well-being of the participant or study staff

2. the analysis of results

• During the Safety Treatment and Follow-up Periods, subjects are not to receive the following:

1. any cannabinoids (CBD, ?9-tetrahydrocannabinol (THC), hemp oil, Realm Oil or marijuana)

2. any other investigational drug or investigational device

Related Conditions & MeSH terms

• Spasm
• Spasms, Infantile

Intervention

Drug:
• Cannabidiol Oral Solution
20 or 40 mg/kg/day BID

Locations

Country	Name	City	State
United States	Mattel Children's Hospital at UCLA	Los Angeles	California
United States	Miami Children's Hospital	Miami	Florida
United States	Beaumont Health System	Royal Oak	Michigan
United States	University of California - San Francisco	San Francisco	California

Sponsors (1)

Lead Sponsor	Collaborator
INSYS Therapeutics Inc

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Part A: Percentage of Participants Who Are Considered Complete Responders at Day 14	Complete response was defined as complete resolution of spasms and hypsarrythmia (if present at baseline) confirmed by video-electroencephalogram (EEG) at Day 14.	Day 14
Primary	Part B: Percentage of Participants Experiencing Adverse Events (AEs), Treatment-Emergent AEs (TEAEs), and Serious Adverse Events (SAEs)		Up to Week 64
Secondary	Part A: Percentage of Participants With Absence of Infantile Spasms at Day 14		Day 14
Secondary	Part A: Percentage of Participants With Absence of Hypsarrhythmia at Day 14		Day 14
Secondary	Part A: Median Reduction in Seizure-burden Comparing Video-EEG at Baseline to Repeat Video-EEG at Day 14		Baseline, Day 14
Secondary	Part A: Parent Impression of Efficacy and Tolerability of Study Drug	Parent impression of efficacy and tolerability, as measured by Clinical Global Impression-Global Improvement Scale (CGI-I), was summarized by visit and status of response (Complete/Partial and No Response) at Visit 3 (Day 14), Visit 4 (Week 4), Visit 5 (Week 8), Visit 6 (Week 10), and end of study. The CGI-I was also analyzed in a continuous scale, as follows: 1 = Very much improved, 2 = Much improved, 3 = Minimally improved, 4 = No change, 5 = Minimally worse, 6 = Much worse, and 7 = Very much worse	Visit 3 (Day 14), Visit 4 (Week 4), Visit 5 (Week 8), Visit 6 (Week 10), and end of study.
Secondary	Part A: Percentage of Participants With a Partial Response to Treatment	Partial response was defined as a substantive change in background EEG or reduction in spasms on video EEG obtained at Day 14.	Day 14
Secondary	Part A: Percentage of Complete Responders With Relapse	Complete response was defined as complete resolution of spasms and hypsarrythmia (if present at baseline) confirmed by video-EEG at Day 14.	Day 14
Secondary	Part A: Time to Complete Responder Relapse	Complete response was defined as complete resolution of spasms and hypsarrythmia (if present at baseline) confirmed by video-EEG at Day 14.	Day 14
Secondary	Part B: Parent Impression of Efficacy and Tolerability of Study Drug as Measured by the Change in Clinical Global Impression of Improvement Assessment (CGI-I), Responses at Every Visit Throughout Part B		Up to Week 64
Secondary	Part B: Investigator Impression of Efficacy and Tolerability of Study Drug as Measured by the Change in CGI-I Responses at Every Visit Throughout Part B		Up to Week 64
Secondary	Part B: Median Reduction in Seizure-burden Comparing Seizure Diaries Throughout Part B.		Up to Week 64
Secondary	Part B: Percentage of Participants Who Have a Relapse of Spasms Based on Video-EEG		Up to Week 64
Secondary	Part B: Time to Relapse as Confirmed by Video-EEG		Up to Week 64